Home LiteratureArticle Details
PMID: 18070707 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Genetic events in the pathogenesis of multiple myeloma.

Best practice & research. Clinical haematology ·Vol. 20 ·No. 4 ·2007-12-00 ·Pages 571-96

Chng WJ, Glebov O, Bergsagel PL, Kuehl WM

Abstract

The genetics of myeloma has been increasingly elucidated in recent years. Recurrent genetic events, and also biologically distinct and clinically relevant genetic subtypes of myeloma have been defined. This has facilitated our understanding of the molecular pathogenesis of the disease. In addition, some genetic abnormalities have proved to be highly reproducible prognostic factors. With the expanding therapeutic armamentarium, it is time to include genetic assessment as part of clinical evaluation of myeloma patients to guide management. In this review we examine the role of various genetic abnormalities in the molecular pathogenesis of myeloma, and the use of such abnormalities in disease classification, prognosis and clinical management.

MeSH Terms
Gene Expression Profiling Humans Immunoglobulin Heavy Chains/genetics Immunoglobulin Light Chains/genetics Karyotyping Multiple Myeloma/classification,genetics,physiopathology NF-kappa B/metabolism Prognosis Translocation, Genetic
Chemicals
Immunoglobulin Heavy Chains Immunoglobulin Light Chains NF-kappa B
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Chng W J
Mayo Clinic Arizona, Scottsdale, AZ 85260, USA.
Glebov O
Bergsagel P L
Kuehl W M
References (103)
103 references, click to expand
  1. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
    Br J Haematol. 2004 Mar;124(5):595-603 PMID: 14871245
  2. Genetics and cytogenetics of multiple myeloma: a workshop report.
    Cancer Res. 2004 Feb 15;64(4):1546-58 PMID: 14989251
  3. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
    Blood. 2001 Feb 1;97(3):729-36 PMID: 11157491
  4. Molecular pathogenesis and a consequent classification of multiple myeloma.
    J Clin Oncol. 2005 Sep 10;23(26):6333-8 PMID: 16155016
  5. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.
    Genes Chromosomes Cancer. 2003 Nov;38(3):234-9 PMID: 14506697
  6. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis.
    Blood. 2001 Oct 1;98(7):2266-8 PMID: 11568015
  7. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
    N Engl J Med. 2003 Dec 25;349(26):2483-94 PMID: 14695408
  8. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.
    Blood. 1998 Dec 1;92(11):4269-78 PMID: 9834233
  9. Prevalence of monoclonal gammopathy of undetermined significance.
    N Engl J Med. 2006 Mar 30;354(13):1362-9 PMID: 16571879
  10. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.
    Blood. 2005 Oct 15;106(8):2837-40 PMID: 15976175
  11. International staging system for multiple myeloma.
    J Clin Oncol. 2005 May 20;23(15):3412-20 PMID: 15809451
  12. Serum test for assessment of patients with Bence Jones myeloma.
    Lancet. 2003 Feb 8;361(9356):489-91 PMID: 12583950
  13. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.
    Blood. 2003 Oct 1;102(7):2562-7 PMID: 12805059
  14. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma.
    Br J Haematol. 2001 Jan;112(1):167-74 PMID: 11167798
  15. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.
    Blood. 2006 Feb 1;107(3):904-6 PMID: 16210333
  16. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.
    Blood. 2002 Sep 1;100(5):1579-83 PMID: 12176874
  17. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.
    Blood. 2005 Jan 1;105(1):317-23 PMID: 15339850
  18. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
    Blood. 2005 Apr 1;105(7):2941-8 PMID: 15598814
  19. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
    Leukemia. 2006 May;20(5):807-13 PMID: 16511510
  20. Distinguishing primary and secondary translocations in multiple myeloma.
    DNA Repair (Amst). 2006 Sep 8;5(9-10):1225-33 PMID: 16829212
  21. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
    Blood. 2002 Aug 15;100(4):1417-24 PMID: 12149226
  22. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.
    Blood. 2002 Mar 15;99(6):2185-91 PMID: 11877296
  23. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
    Blood. 2006 May 15;107(10):4039-46 PMID: 16467200
  24. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.
    Blood. 2000 Mar 15;95(6):1925-30 PMID: 10706856
  25. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
    Blood. 1998 Jun 15;91(12):4457-63 PMID: 9616139
  26. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
    Blood. 2001 Jul 1;98(1):217-23 PMID: 11418483
  27. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
    Clin Chem. 2005 May;51(5):878-81 PMID: 15774572
  28. Rare occurrence of P53 gene mutations in multiple myeloma.
    Br J Haematol. 1992 Jul;81(3):440-3 PMID: 1390218
  29. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
    Cancer Res. 2007 Apr 1;67(7):2982-9 PMID: 17409404
  30. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.
    Blood. 2005 Jan 1;105(1):358-60 PMID: 15339849
  31. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
    Blood. 2007 Apr 15;109(8):3489-95 PMID: 17209057
  32. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
    Blood. 2003 Mar 15;101(6):2374-6 PMID: 12433679
  33. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.
    Nature. 2001 Jul 19;412(6844):341-6 PMID: 11460166
  34. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis.
    Blood. 1985 Aug;66(2):380-90 PMID: 3926026
  35. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
    Blood. 2007 Feb 15;109(4):1692-700 PMID: 17023574
  36. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.
    Blood. 2005 Aug 1;106(3):812-7 PMID: 15855274
  37. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
    Br J Haematol. 2003 Jun;121(5):749-57 PMID: 12780789
  38. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
    Blood. 1998 Aug 1;92(3):802-9 PMID: 9680348
  39. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique.
    Blood. 2001 Feb 1;97(3):822-5 PMID: 11157506
  40. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.
    Cell Div. 2006 Oct 18;1:23 PMID: 17049078
  41. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
    Blood. 2001 Nov 15;98(10):3082-6 PMID: 11698294
  42. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.
    Br J Haematol. 2004 Apr;125(1):64-8 PMID: 15015970
  43. Chromosome translocations in multiple myeloma.
    Oncogene. 2001 Sep 10;20(40):5611-22 PMID: 11607813
  44. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
    Leukemia. 2007 Jan;21(1):143-50 PMID: 17024116
  45. Mechanisms of B-cell lymphoma pathogenesis.
    Nat Rev Cancer. 2005 Apr;5(4):251-62 PMID: 15803153
  46. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
    Blood. 1996 Oct 1;88(7):2699-706 PMID: 8839865
  47. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
    Cancer Cell. 2004 Feb;5(2):191-9 PMID: 14998494
  48. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.
    Br J Haematol. 2002 Sep;118(4):1041-7 PMID: 12199783
  49. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.
    Blood. 2007 Feb 1;109(3):1228-32 PMID: 16840723
  50. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations.
    Jpn J Cancer Res. 2001 Jun;92(6):638-44 PMID: 11429052
  51. Multiple myeloma: evolving genetic events and host interactions.
    Nat Rev Cancer. 2002 Mar;2(3):175-87 PMID: 11990854
  52. The molecular classification of multiple myeloma.
    Blood. 2006 Sep 15;108(6):2020-8 PMID: 16728703
  53. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance.
    Blood. 2001 Aug 15;98(4):1271-2 PMID: 11510469
  54. Immunoglobulin synthesis and tumor kinetics of multiple myeloma.
    Semin Hematol. 1973 Apr;10(2):135-44 PMID: 4266778
  55. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases.
    Leukemia. 1998 Jun;12(6):960-9 PMID: 9639426
  56. Germline CDKN2A mutation implicated in predisposition to multiple myeloma.
    Blood. 2000 Mar 1;95(5):1869-71 PMID: 10688850
  57. Cytogenetic findings in 200 patients with multiple myeloma.
    Cancer Genet Cytogenet. 1995 Jul 1;82(1):41-9 PMID: 7627933
  58. Clinical significance of TP53 mutation in myeloma.
    Leukemia. 2007 Mar;21(3):582-4 PMID: 17215851
  59. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
    Blood. 1998 Nov 1;92(9):3025-34 PMID: 9787135
  60. Hypodiploidy is a major prognostic factor in multiple myeloma.
    Blood. 2001 Oct 1;98(7):2229-38 PMID: 11568011
  61. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma.
    Blood. 2007 Feb 1;109(3):1337-8 PMID: 17244692
  62. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
    Hum Mutat. 2001 Sep;18(3):212-24 PMID: 11524732
  63. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.
    Blood. 2000 Aug 15;96(4):1505-11 PMID: 10942398
  64. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
    Mayo Clin Proc. 2007 Mar;82(3):323-41 PMID: 17352369
  65. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance.
    Leukemia. 2000 Nov;14(11):1975-9 PMID: 11069034
  66. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma.
    Cancer Genet Cytogenet. 1999 Aug;113(1):73-7 PMID: 10459351
  67. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
    Blood. 2007 Mar 15;109(6):2276-84 PMID: 17105813
  68. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13.
    Br J Haematol. 2000 Dec;111(4):1116-7 PMID: 11227093
  69. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.
    Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):228-33 PMID: 10618400
  70. Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.
    Blood. 2007 Apr 15;109(8):3610-1 PMID: 17409348
  71. t(11;14) does not predict long-term survival in myeloma.
    Leukemia. 2005 Jun;19(6):1078-9 PMID: 15815719
  72. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy.
    Blood. 1993 Jan 1;81(1):128-35 PMID: 8417784
  73. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
    Cancer Res. 2002 Feb 1;62(3):715-20 PMID: 11830525
  74. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
    Blood. 2001 Mar 15;97(6):1566-71 PMID: 11238092
  75. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
    N Engl J Med. 2002 Feb 21;346(8):564-9 PMID: 11856795
  76. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
    Blood. 2002 May 15;99(10):3735-41 PMID: 11986230
  77. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
    Blood. 2005 Jul 1;106(1):296-303 PMID: 15755896
  78. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
    Leukemia. 2007 Mar;21(3):529-34 PMID: 17230230
  79. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation.
    Cell Cycle. 2005 Feb;4(2):330-8 PMID: 15684604
  80. Regulation of plasma-cell development.
    Nat Rev Immunol. 2005 Mar;5(3):230-42 PMID: 15738953
  81. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
    Blood. 2003 Jun 1;101(11):4569-75 PMID: 12576322
  82. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.
    Oncogene. 2005 Oct 20;24(46):6936-44 PMID: 16044163
  83. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Leuk Res. 2007 Jun;31(6):779-82 PMID: 16996589
  84. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.
    Blood. 1996 Jul 15;88(2):674-81 PMID: 8695815
  85. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
    J Clin Oncol. 2005 Oct 1;23(28):7069-73 PMID: 16129840
  86. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
    Blood. 2003 Feb 15;101(4):1520-9 PMID: 12393535
  87. Phenotypic heterogeneity in multiple myeloma families.
    J Clin Oncol. 2005 Feb 1;23(4):685-93 PMID: 15681516
  88. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
    Leukemia. 2006 Nov;20(11):2034-40 PMID: 17024118
  89. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
    Leukemia. 1994 May;8(5):758-67 PMID: 8182933
  90. t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients.
    Br J Haematol. 2003 Jan;120(1):170-1 PMID: 12492597
  91. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
    Blood. 2006 Oct 1;108(7):2165-72 PMID: 16772605
  92. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.
    Leukemia. 2001 Jun;15(6):981-6 PMID: 11417487
  93. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
    J Clin Oncol. 2005 Sep 10;23(26):6339-44 PMID: 16155017
  94. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
    Blood. 2005 May 15;105(10):4060-9 PMID: 15677557
  95. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
    Blood. 2007 Jun 1;109(11):4995-5001 PMID: 17303695
  96. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
    Cancer Cell. 2006 Apr;9(4):313-25 PMID: 16616336
  97. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
    Nat Genet. 1997 Jul;16(3):260-4 PMID: 9207791
  98. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.
    Cancer Res. 1999 Sep 15;59(18):4546-50 PMID: 10493504
  99. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.
    Blood. 2004 May 1;103(9):3521-8 PMID: 14715624
  100. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
    Blood. 2006 Sep 1;108(5):1724-32 PMID: 16705089
  101. Cancer statistics, 2007.
    CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 PMID: 17237035
  102. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.
    Br J Haematol. 2006 Nov;135(4):486-91 PMID: 16995883
  103. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma.
    Br J Haematol. 1997 Aug;98(2):418-25 PMID: 9266942
Article Info
Journal
Best practice & research. Clinical haematology
Abbr.
Best Pract Res Clin Haematol
ISSN
1521-6926
DOI
10.1016/j.beha.2007.08.004
Published
2007-12-00
Pages
571-96
Language
English
Region
Netherlands
NLM ID
101120659
PMCID
PMC2198931
Subset
IM
Grants
NCI NIH HHS · K01 CA074265-04 · United States
NIA NIH HHS · R01 AG020686-01A1 · United States
NIA NIH HHS · R01 AG020686 · United States
NIA NIH HHS · R01 AG020686-04 · United States
NIA NIH HHS · R01 AG020686-05 · United States
NIA NIH HHS · R01 AG020686-03 · United States
NCI NIH HHS · K01 CA074265-03 · United States
NCI NIH HHS · P50 CA100707-010004 · United States
NCI NIH HHS · P50 CA100707 · United States
NCI NIH HHS · K01 CA074265-05 · United States
NIA NIH HHS · R01 AG020686-02 · United States
External Links
PubMed source DOI: 10.1016/j.beha.2007.08.004 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2